AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Inflazome Receives Funding from The Michael J. Fox Foundation for Parkinson’s Research

March 25, 2019

DUBLIN & CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--Mar 25, 2019--Inflazome ( inflazome.com ), the pioneering biotech company developing several small molecule drugs that inhibit harmful inflammation, today announces it has been awarded funding in excess of US$1 million by The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The grant will fund the development of a NLRP3-specific Positron Emission Tomography (PET) tracer to allow non-invasive imaging of inflammasome-driven inflammation in the brain.

To enhance the accuracy and probability of success of a clinical trial in neurodegenerative disease, it is important to select suitable patients at the appropriate staging of the disease. It is also essential to determine whether the biological target of interest is being engaged by the drug in the brain. One approach to achieve this in the central nervous system (CNS) is by using an NLRP3-specific tracer during a PET scan. The tracer could quickly, accurately and non-invasively produce images showing the drug binding to target inflammasomes in the brain.

The NLRP3 inflammasome is believed to drive chronic inflammation associated with the progression of many neurodegenerative diseases, including Parkinson’s Disease. The PET tracer will also help Inflazome to determine what doses are needed for patients in larger clinical trials in the future. The Principal Investigator on this project is Prof. Matthew Cooper, CEO and co-founder of Inflazome, who is assisted by Co-Investigator Dr David Miller, Head of Medicinal Chemistry.

Inflazome is developing orally available drugs to address clinical unmet needs in inflammatory diseases by targeting the NLRP3 inflammasome, which is now understood to drive many chronic and acute inflammatory conditions. The NLRP3 inflammasome was recently shown to be associated with the progression of Parkinson’s Disease in humans and in non-clinical models, in research published on 31 October 2018 in Science Translational Medicine ( Link ).

This innovative research was co-authored by Prof. Cooper with research teams at The University of Queensland, Australia, led by A/Prof. Trent Woodruff and funded by The Michael J. Fox Foundation for Parkinson’s Research and the Shake It Up Australia Foundation.

Prof Matt Cooper, Co-Founder and CEO of Inflazome, commented: “The Michael J. Fox Foundation is a fantastic organisation with a passionate commitment to new science, science translation and candidate therapies for Parkinson’s. We are fully aligned in our shared goal to help patients with Parkinson’s and other debilitating neurodegenerative diseases, for which there are inadequate therapies and no cures. Their support will help us advance and hopefully validate our disruptive approach to diagnose and then treat patients by focusing on neuroinflammation.”

Dr Jamie Eberling, Director of Research Programs at MJFF, said, “An imaging tool to visualize neuroinflammation may help investigate Parkinson’s onset and progression as well as evaluate new treatments that could alter the course of the disease. Our Foundation is investing in this research due to the significant potential impact on drug development and patient lives.”

About Parkinson’s Disease

Parkinson’s disease is the second most common neurodegenerative disorder worldwide, affecting more than 10 million people. It is characterised by the loss of dopamine-producing neurons, accompanied by chronic inflammation in the brain. Inflazome has identified drugs to stop the chronic cycle of inflammation in the brain. Research published in Science Translational Medicine on 31 October 2018 found that the tool compound MCC950, a potent inhibitor of the NLRP3 inflammasome, given orally once a day could stop neuroinflammation. MCC950 arrested the effects of Parkinson’s in several animal models of the disease, leading to reduced brain neuron loss and higher levels of dopamine.

A link to a Parkinson’s Disease explainer video can be found here

About Inflazome

To learn more please visit:  inflazome.com

About The Michael J. Fox Foundation for Parkinson’s Research

To learn more please visit: https://www.michaeljfox.org/

View source version on businesswire.com:https://www.businesswire.com/news/home/20190325005126/en/

CONTACT: Inflazome:

Dr Jeremy Skillington | VP Business Development

E:j.skillington@inflazome.comMedia Contacts:

FTI Consulting (Ireland)

Jonathan Neilan, Paddy Berkery

E:jonathan.neilan@fticonsulting.com;patrick.berkery@fticonsulting.com

T: +353 (1) 765 0884FTI Consulting (UK)

Brett Pollard, Ciara Martin

E:brett.pollard@fticonsulting.com;ciara.martin@fticonsulting.com

T: +44 (0) 20 3727 1000

KEYWORD: UNITED KINGDOM EUROPE IRELAND

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL

SOURCE: Inflazome

Copyright Business Wire 2019.

PUB: 03/25/2019 03:00 AM/DISC: 03/25/2019 03:01 AM

http://www.businesswire.com/news/home/20190325005126/en